UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act File Number: 811-23494
T. Rowe Price Exchange-Traded Funds, Inc.
(Exact name of registrant as specified in charter)
100 East Pratt Street, Baltimore, MD 21202
(Address of principal executive offices)
David Oestreicher
100 East Pratt Street, Baltimore, MD 21202
(Name and address of agent for service)
Registrant’s telephone number, including area code: (410) 345-2000
Date of fiscal year end: December 31
Date of reporting period: June 30, 2024
Item 1. Reports to Shareholders
(a) Report pursuant to Rule 30e-1
Semi-Annual Shareholder Report
June 30, 2024
U.S. Equity Research ETF (TSPA)
Principal Listing Exchange: NYSE Arca, Inc.
This semiannual shareholder report contains important information about U.S. Equity Research ETF ("the fund") for the period of January 1, 2024 to June 30, 2024. You can find the fund’s prospectus, financial information on Form N-CSR (which includes required tax information for dividends), holdings, proxy voting information, and other information at www.troweprice.com/prospectus. You can also request this information without charge by contacting T. Rowe Price at 1-800-638-5660 or info@troweprice.com or by contacting your intermediary.
What were the fund costs for the last year? (based on a hypothetical $10,000 investment)
| Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment |
|---|
| U.S. Equity Research ETF | $18 | 0.34% |
What are some fund statistics?
- Total Net Assets (000s)$730,051
- Number of Portfolio Holdings339
- Portfolio Turnover Rate23.2%
What did the fund invest in?
Sector Allocation (as a % of Net Assets)
| Information Technology | 32.4% |
| Financials | 12.8 |
| Health Care | 12.4 |
| Consumer Discretionary | 9.9 |
| Communication Services | 9.2 |
| Industrials & Business Services | 7.4 |
| Consumer Staples | 5.7 |
| Energy | 3.8 |
| Utilities | 2.2 |
| Other | 4.2 |
Top Ten Holdings (as a % of Net Assets)
| Microsoft | 7.3% |
| NVIDIA | 7.1 |
| Apple | 6.8 |
| Alphabet | 4.3 |
| Amazon.com | 3.9 |
| Meta Platforms | 2.5 |
| Eli Lilly | 2.0 |
| Broadcom | 1.5 |
| Tesla | 1.2 |
| Exxon Mobil | 1.2 |
If you invest directly with T. Rowe Price, you can elect to receive future shareholder reports or other important documents through electronic delivery by enrolling at www.troweprice.com/paperless. If you invest through a financial intermediary such as an investment advisor, a bank, retirement plan sponsor or a brokerage firm, please contact that organization and ask if it can provide electronic delivery.
T. Rowe Price Investment Services, Inc.
100 East Pratt Street
Baltimore, MD 21202
U.S. Equity Research ETF (TSPA)
Principal Listing Exchange: NYSE Arca, Inc.
Item 1. (b) Notice pursuant to Rule 30e-3.
Not applicable.
Item 2. Code of Ethics.
A code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions is filed as an exhibit to the registrant’s annual Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics during the registrant’s most recent fiscal half-year.
Item 3. Audit Committee Financial Expert.
Disclosure required in registrant’s annual Form N-CSR.
Item 4. Principal Accountant Fees and Services.
Disclosure required in registrant’s annual Form N-CSR.
Item 5. Audit Committee of Listed Registrants.
Not applicable.
Item 6. Investments.
(a) Not applicable. The complete schedule of investments is included in Item 7 of this Form N-CSR.
(b) Not applicable.
Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.
(a – b) Report pursuant to Regulation S-X.
Financial Statements and Other Information
June 30, 2024
| | T. ROWE PRICE |
| TSPA | U.S. Equity Research ETF |
| | For more insights from T. Rowe Price investment professionals, go to troweprice.com. |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Unaudited
For a share outstanding throughout each period
| | 6 Months
Ended | Year
Ended | | 6/8/21(1)
Through |
| | 6/30/24 | 12/31/23 | 12/31/22 | 12/31/21 |
| NET ASSET VALUE | | | | |
| Beginning of period | $ 29.36 | $ 22.72 | $ 28.25 | $ 25.00 |
| Investment activities | | | | |
| Net investment income(2) (3) | 0.16 | 0.31 | 0.26 | 0.14 |
| Net realized and unrealized gain/loss | 4.83 | 6.45 | (5.53) | 3.23 |
| Total from investment activities | 4.99 | 6.76 | (5.27) | 3.37 |
| Distributions | | | | |
| Net investment income | - | (0.12) | (0.23) | (0.12) |
| Net realized gain | - | - | (0.03) | - |
| Total distributions | - | (0.12) | (0.26) | (0.12) |
| NET ASSET VALUE | | | | |
| End of period | $ 34.35 | $ 29.36 | $ 22.72 | $ 28.25 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Unaudited
For a share outstanding throughout each period
| | 6 Months
Ended | Year
Ended | | 6/8/21(1)
Through |
| | 6/30/24 | 12/31/23 | 12/31/22 | 12/31/21 |
| Ratios/Supplemental Data |
| Total return, based on NAV(3) (4) | 17.00% | 29.77% | (18.64)% | 13.51% |
Ratios to average net
assets:(3) | | | | |
Gross expenses before
waivers/payments by
Price Associates | 0.34%(5) | 0.34% | 0.34% | 0.34%(5) |
Net expenses after
waivers/payments by
Price Associates | 0.34%(5) | 0.34% | 0.34% | 0.34%(5) |
| Net investment income | 0.97%(5) | 1.18% | 1.05% | 0.92%(5) |
| Portfolio turnover rate(6) | 23.2% | 42.2% | 39.9% | 13.0% |
Net assets, end of period
(in thousands) | $ 730,051 | $ 95,116 | $ 23,064 | $ 23,165 |
| (1) | Inception date |
| (2) | Per share amounts calculated using average shares outstanding method. |
| (3) | Includes the impact of expense-related arrangements with Price Associates. |
| (4) | Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions. Total return is not annualized for periods less than one year. |
| (5) | Annualized |
| (6) | Portfolio turnover excludes securities received or delivered through in-kind share transactions. |
The accompanying notes are an integral part of these financial statements.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
June 30, 2024 Unaudited
| PORTFOLIO OF INVESTMENTS‡ | Shares | $ Value |
| (Cost and value in $000s) | | |
| | | |
| COMMON STOCKS 99.7% |
| COMMUNICATION SERVICES 9.2% |
| Diversified Telecommunication Services 0.1% | | |
| Verizon Communications | 19,529 | 805 |
| | | 805 |
| Entertainment 1.1% | | |
| Netflix (1) | 9,442 | 6,372 |
| Walt Disney | 16,281 | 1,617 |
| | | 7,989 |
| Interactive Media & Services 6.8% | | |
| Alphabet, Class A | 71,346 | 12,996 |
| Alphabet, Class C | 100,330 | 18,402 |
| Meta Platforms, Class A | 36,012 | 18,158 |
| | | 49,556 |
| Media 0.4% | | |
| Comcast, Class A | 79,309 | 3,106 |
| | | 3,106 |
| Wireless Telecommunication Services 0.8% | | |
| T-Mobile US | 33,154 | 5,841 |
| | | 5,841 |
| Total Communication Services | | 67,297 |
| CONSUMER DISCRETIONARY 9.9% |
| Automobile Components 0.0% | | |
| Aptiv (1) | 3,737 | 263 |
| | | 263 |
| Automobiles 1.3% | | |
| Ford Motor | 2,900 | 36 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| General Motors | 7,766 | 361 |
| Rivian Automotive, Class A (1)(2) | 22,569 | 303 |
| Tesla (1) | 44,073 | 8,721 |
| | | 9,421 |
| Broadline Retail 4.0% | | |
| Amazon.com (1) | 148,954 | 28,786 |
| | | 28,786 |
| Hotels, Restaurants & Leisure 2.5% | | |
| Airbnb, Class A (1) | 8,432 | 1,279 |
| Booking Holdings | 570 | 2,258 |
| Chipotle Mexican Grill (1) | 44,100 | 2,763 |
| Domino's Pizza | 1,628 | 841 |
| Hilton Worldwide Holdings | 6,775 | 1,478 |
| Las Vegas Sands | 21,228 | 939 |
| Marriott International, Class A | 5,197 | 1,256 |
| McDonald's | 14,363 | 3,660 |
| Norwegian Cruise Line Holdings (1) | 16,924 | 318 |
| Royal Caribbean Cruises (1) | 7,776 | 1,240 |
| Starbucks | 7,289 | 567 |
| Wingstop | 1,476 | 624 |
| Wynn Resorts | 8,411 | 753 |
| Yum! Brands | 4,300 | 570 |
| | | 18,546 |
| Household Durables 0.2% | | |
| NVR (1) | 170 | 1,290 |
| | | 1,290 |
| Specialty Retail 1.8% | | |
| AutoZone (1) | 311 | 922 |
| Bath & Body Works | 4,432 | 173 |
| Burlington Stores (1) | 2,793 | 670 |
| Home Depot | 17,076 | 5,878 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Lowe's | 8,393 | 1,851 |
| O'Reilly Automotive (1) | 1,012 | 1,069 |
| Ross Stores | 8,934 | 1,298 |
| TJX | 12,876 | 1,418 |
| Ulta Beauty (1) | 200 | 77 |
| | | 13,356 |
| Textiles, Apparel & Luxury Goods 0.1% | | |
| NIKE, Class B | 8,932 | 673 |
| | | 673 |
| Total Consumer Discretionary | | 72,335 |
| CONSUMER STAPLES 5.7% |
| Beverages 1.6% | | |
| Coca-Cola | 72,176 | 4,594 |
| Constellation Brands, Class A | 4,381 | 1,127 |
| Keurig Dr Pepper | 49,535 | 1,654 |
| Monster Beverage (1) | 11,146 | 557 |
| PepsiCo | 21,923 | 3,616 |
| | | 11,548 |
| Consumer Staples Distribution & Retail 1.9% | | |
| Costco Wholesale | 7,159 | 6,085 |
| Dollar General | 8,559 | 1,132 |
| Sysco | 4,329 | 309 |
| Target | 8,486 | 1,256 |
| Walmart | 71,983 | 4,874 |
| | | 13,656 |
| Food Products 0.3% | | |
| Kraft Heinz | 9,905 | 319 |
| Mondelez International, Class A | 21,048 | 1,378 |
| Tyson Foods, Class A | 4,238 | 242 |
| | | 1,939 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Household Products 1.2% | | |
| Colgate-Palmolive | 25,002 | 2,426 |
| Kimberly-Clark | 2,300 | 318 |
| Procter & Gamble | 37,497 | 6,184 |
| | | 8,928 |
| Personal Care Products 0.2% | | |
| elf Beauty (1) | 1,045 | 220 |
| Kenvue | 64,712 | 1,177 |
| | | 1,397 |
| Tobacco 0.5% | | |
| Altria Group | 7,933 | 361 |
| Philip Morris International | 33,966 | 3,442 |
| | | 3,803 |
| Total Consumer Staples | | 41,271 |
| ENERGY 3.8% |
| Energy Equipment & Services 0.3% | | |
| Halliburton | 23,552 | 796 |
| Schlumberger | 33,873 | 1,598 |
| | | 2,394 |
| Oil, Gas & Consumable Fuels 3.5% | | |
| Chesapeake Energy | 3,767 | 310 |
| Chevron | 24,374 | 3,813 |
| ConocoPhillips | 31,107 | 3,558 |
| Devon Energy | 2,800 | 133 |
| Diamondback Energy | 4,236 | 848 |
| EOG Resources | 12,684 | 1,596 |
| EQT | 12,511 | 463 |
| Exxon Mobil | 75,304 | 8,669 |
| Hess | 3,678 | 542 |
| Kinder Morgan | 34,200 | 679 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Marathon Petroleum | 12,279 | 2,130 |
| Phillips 66 | 3,880 | 548 |
| Suncor Energy | 8,425 | 321 |
| Targa Resources | 5,600 | 721 |
| Valero Energy | 4,228 | 663 |
| Williams | 6,060 | 257 |
| | | 25,251 |
| Total Energy | | 27,645 |
| FINANCIALS 12.8% |
| Banks 3.2% | | |
| Bank of America | 106,162 | 4,222 |
| Citigroup | 52,664 | 3,342 |
| East West Bancorp | 4,528 | 332 |
| Fifth Third Bancorp | 32,471 | 1,185 |
| Huntington Bancshares | 75,815 | 999 |
| JPMorgan Chase | 42,765 | 8,650 |
| M&T Bank | 100 | 15 |
| PNC Financial Services Group | 3,967 | 617 |
| Popular | 700 | 62 |
| Truist Financial | 9,498 | 369 |
| Wells Fargo | 57,841 | 3,435 |
| Western Alliance Bancorp | 4,288 | 269 |
| | | 23,497 |
| Capital Markets 2.6% | | |
| Ares Management | 6,783 | 904 |
| Bank of New York Mellon | 17,478 | 1,047 |
| BlackRock | 1,282 | 1,009 |
| Blackstone | 5,067 | 627 |
| Cboe Global Markets | 5,008 | 852 |
| Charles Schwab | 39,935 | 2,943 |
| CME Group | 1,027 | 202 |
| FactSet Research Systems | 100 | 41 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Goldman Sachs Group | 4,558 | 2,062 |
| Intercontinental Exchange | 12,285 | 1,682 |
| KKR | 12,180 | 1,282 |
| LPL Financial Holdings | 449 | 125 |
| Moody's | 2,382 | 1,003 |
| Morgan Stanley | 21,345 | 2,074 |
| MSCI | 1,107 | 533 |
| S&P Global | 5,114 | 2,281 |
| Tradeweb Markets, Class A | 5,406 | 573 |
| | | 19,240 |
| Consumer Finance 0.6% | | |
| Ally Financial | 10,217 | 405 |
| American Express | 12,476 | 2,889 |
| Capital One Financial | 2,225 | 308 |
| Discover Financial Services | 4,899 | 641 |
| Synchrony Financial | 6,792 | 320 |
| | | 4,563 |
| Financial Services 4.4% | | |
| Apollo Global Management | 4,439 | 524 |
| Berkshire Hathaway, Class B (1) | 21,178 | 8,615 |
| Corebridge Financial | 43,945 | 1,280 |
| Corpay (1) | 4,472 | 1,192 |
| Equitable Holdings | 15,545 | 635 |
| Fiserv (1) | 20,841 | 3,106 |
| Global Payments | 11,244 | 1,087 |
| Mastercard, Class A | 14,042 | 6,195 |
| Visa, Class A | 29,877 | 7,842 |
| Voya Financial | 16,868 | 1,200 |
| | | 31,676 |
| Insurance 2.0% | | |
| Allstate | 9,478 | 1,513 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| American International Group | 29,530 | 2,192 |
| Axis Capital Holdings | 1,097 | 77 |
| Chubb | 12,887 | 3,287 |
| Hartford Financial Services Group | 21,034 | 2,115 |
| Marsh & McLennan | 8,712 | 1,836 |
| MetLife | 24,791 | 1,740 |
| RenaissanceRe Holdings | 4,710 | 1,053 |
| Travelers | 3,447 | 701 |
| | | 14,514 |
| Total Financials | | 93,490 |
| HEALTH CARE 12.4% |
| Biotechnology 1.8% | | |
| AbbVie | 24,353 | 4,177 |
| Amgen | 10,355 | 3,236 |
| Biogen (1) | 4,007 | 929 |
| Gilead Sciences | 8,138 | 558 |
| Moderna (1) | 85 | 10 |
| Regeneron Pharmaceuticals (1) | 1,859 | 1,954 |
| Vertex Pharmaceuticals (1) | 5,319 | 2,493 |
| | | 13,357 |
| Health Care Equipment & Supplies 2.4% | | |
| Abbott Laboratories | 12,991 | 1,350 |
| Baxter International | 6,193 | 207 |
| Becton Dickinson | 8,212 | 1,919 |
| Boston Scientific (1) | 20,563 | 1,584 |
| Dexcom (1) | 11,947 | 1,355 |
| Edwards Lifesciences (1) | 17,385 | 1,606 |
| Hologic (1) | 12,492 | 927 |
| IDEXX Laboratories (1) | 260 | 127 |
| Intuitive Surgical (1) | 7,292 | 3,244 |
| Medtronic | 9,030 | 711 |
| Solventum (1) | 216 | 11 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Stryker | 8,198 | 2,789 |
| Teleflex | 486 | 102 |
| Zimmer Biomet Holdings | 14,351 | 1,557 |
| | | 17,489 |
| Health Care Providers & Services 2.7% | | |
| Cardinal Health | 4,167 | 410 |
| Cencora | 3,896 | 878 |
| Centene (1) | 2,394 | 159 |
| Cigna | 8,219 | 2,717 |
| CVS Health | 2,776 | 164 |
| Elevance Health | 5,356 | 2,902 |
| HCA Healthcare | 284 | 91 |
| Humana | 2,018 | 754 |
| McKesson | 2,941 | 1,718 |
| Molina Healthcare (1) | 2,200 | 654 |
| Tenet Healthcare (1) | 8,286 | 1,102 |
| UnitedHealth Group | 15,828 | 8,060 |
| | | 19,609 |
| Life Sciences Tools & Services 1.4% | | |
| Agilent Technologies | 1,452 | 188 |
| Bio-Techne | 4,120 | 295 |
| Charles River Laboratories International (1) | 200 | 42 |
| Danaher | 13,177 | 3,292 |
| ICON (1) | 1,982 | 622 |
| IQVIA Holdings (1) | 72 | 15 |
| Mettler-Toledo International (1) | 466 | 651 |
| Repligen (1) | 4,500 | 567 |
| Thermo Fisher Scientific | 8,164 | 4,515 |
| | | 10,187 |
| Pharmaceuticals 4.1% | | |
| AstraZeneca, ADR | 18,564 | 1,448 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Bristol-Myers Squibb | 17,083 | 709 |
| Elanco Animal Health (1) | 33,500 | 483 |
| Eli Lilly | 15,891 | 14,387 |
| Johnson & Johnson | 30,171 | 4,410 |
| Merck | 36,759 | 4,551 |
| Novo Nordisk, ADR | 8,999 | 1,285 |
| Pfizer | 24,960 | 698 |
| Sanofi, ADR | 1,700 | 83 |
| Viatris | 87,631 | 932 |
| Zoetis | 5,920 | 1,026 |
| | | 30,012 |
| Total Health Care | | 90,654 |
| INDUSTRIALS & BUSINESS SERVICES 7.4% |
| Aerospace & Defense 1.7% | | |
| Boeing (1) | 12,465 | 2,269 |
| General Dynamics | 1,681 | 488 |
| General Electric | 24,134 | 3,836 |
| Howmet Aerospace | 11,879 | 922 |
| Huntington Ingalls Industries | 383 | 94 |
| L3Harris Technologies | 6,746 | 1,515 |
| Lockheed Martin | 366 | 171 |
| Northrop Grumman | 2,255 | 983 |
| RTX | 10,458 | 1,050 |
| TransDigm Group | 1,112 | 1,421 |
| | | 12,749 |
| Air Freight & Logistics 0.2% | | |
| FedEx | 4,474 | 1,342 |
| | | 1,342 |
| Building Products 0.4% | | |
| Carrier Global | 20,401 | 1,287 |
| Johnson Controls International | 8,696 | 578 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Trane Technologies | 2,409 | 792 |
| | | 2,657 |
| Commercial Services & Supplies 0.5% | | |
| Cintas | 1,163 | 814 |
| Copart (1) | 19,774 | 1,071 |
| Republic Services | 1,700 | 330 |
| Veralto | 619 | 59 |
| Waste Connections | 6,298 | 1,105 |
| Waste Management | 2,300 | 491 |
| | | 3,870 |
| Construction & Engineering 0.0% | | |
| WillScot Mobile Mini Holdings (1) | 4,150 | 156 |
| | | 156 |
| Electrical Equipment 0.7% | | |
| Emerson Electric | 4,465 | 492 |
| GE Vernova (1) | 11,622 | 1,993 |
| Hubbell | 2,089 | 764 |
| Rockwell Automation | 4,628 | 1,274 |
| Vertiv Holdings, Class A | 2,700 | 234 |
| | | 4,757 |
| Ground Transportation 1.5% | | |
| Canadian National Railway | 6,216 | 734 |
| Canadian Pacific Kansas City (2) | 3,452 | 272 |
| CSX | 60,252 | 2,016 |
| JB Hunt Transport Services | 4,005 | 641 |
| Norfolk Southern | 5,492 | 1,179 |
| Old Dominion Freight Line | 12,831 | 2,266 |
| Saia (1) | 1,310 | 621 |
| Uber Technologies (1) | 39,946 | 2,903 |
| | | 10,632 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Industrial Conglomerates 0.7% | | |
| 3M | 1,675 | 171 |
| Honeywell International | 12,801 | 2,734 |
| Roper Technologies | 3,559 | 2,006 |
| | | 4,911 |
| Machinery 1.3% | | |
| Caterpillar | 3,677 | 1,225 |
| Cummins | 7,135 | 1,976 |
| Deere | 4,197 | 1,568 |
| Dover | 4,167 | 752 |
| Esab | 3,580 | 338 |
| IDEX | 3,104 | 624 |
| Ingersoll-Rand | 10,520 | 956 |
| Nordson | 569 | 132 |
| Otis Worldwide | 1,581 | 152 |
| Stanley Black & Decker | 23,386 | 1,868 |
| Xylem | 500 | 68 |
| | | 9,659 |
| Passenger Airlines 0.1% | | |
| Southwest Airlines | 13,085 | 374 |
| United Airlines Holdings (1) | 6,240 | 304 |
| | | 678 |
| Professional Services 0.3% | | |
| Broadridge Financial Solutions | 3,638 | 717 |
| Equifax | 1,912 | 463 |
| TransUnion | 3,452 | 256 |
| Verisk Analytics | 2,827 | 762 |
| | | 2,198 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Trading Companies & Distributors 0.0% | | |
| SiteOne Landscape Supply (1) | 1,823 | 221 |
| | | 221 |
| Total Industrials & Business Services | | 53,830 |
| INFORMATION TECHNOLOGY 32.4% |
| Communications Equipment 0.4% | | |
| Arista Networks (1) | 2,802 | 982 |
| Cisco Systems | 40,157 | 1,908 |
| | | 2,890 |
| Electronic Equipment, Instruments & Components 0.9% | | |
| Amphenol, Class A | 34,710 | 2,339 |
| Keysight Technologies (1) | 7,052 | 964 |
| TE Connectivity | 9,285 | 1,397 |
| Teledyne Technologies (1) | 2,642 | 1,025 |
| Zebra Technologies, Class A (1) | 2,862 | 884 |
| | | 6,609 |
| IT Services 0.8% | | |
| Accenture, Class A | 13,585 | 4,122 |
| Gartner (1) | 200 | 90 |
| International Business Machines | 8,034 | 1,389 |
| Shopify, Class A (1) | 1,700 | 112 |
| | | 5,713 |
| Semiconductors & Semiconductor Equipment 12.0% | | |
| Advanced Micro Devices (1) | 11,999 | 1,946 |
| Analog Devices | 4,289 | 979 |
| Applied Materials | 4,219 | 996 |
| ASML Holding NV | 36 | 37 |
| Broadcom | 6,879 | 11,044 |
| Entegris | 9,645 | 1,306 |
| First Solar (1) | 45 | 10 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| KLA | 4,257 | 3,510 |
| Lam Research | 4,370 | 4,653 |
| Lattice Semiconductor (1) | 4,270 | 248 |
| Microchip Technology | 7,934 | 726 |
| Micron Technology | 21,575 | 2,838 |
| Monolithic Power Systems | 972 | 799 |
| NVIDIA | 418,080 | 51,650 |
| QUALCOMM | 25,410 | 5,061 |
| Teradyne | 4,764 | 706 |
| Texas Instruments | 6,005 | 1,168 |
| | | 87,677 |
| Software 11.4% | | |
| Adobe (1) | 8,269 | 4,594 |
| Autodesk (1) | 6,047 | 1,496 |
| Cadence Design Systems (1) | 4,547 | 1,399 |
| Crowdstrike Holdings, Class A (1) | 2,200 | 843 |
| Descartes Systems Group (1) | 7,144 | 692 |
| Dynatrace (1) | 8,834 | 395 |
| Fair Isaac (1) | 569 | 847 |
| Fortinet (1) | 35,026 | 2,111 |
| Gen Digital | 58,907 | 1,471 |
| Intuit | 4,001 | 2,630 |
| Microsoft | 119,384 | 53,359 |
| Oracle | 18,901 | 2,669 |
| Palo Alto Networks (1) | 2,433 | 825 |
| Salesforce.com | 22,410 | 5,762 |
| ServiceNow (1) | 596 | 469 |
| Synopsys (1) | 4,859 | 2,891 |
| Tyler Technologies (1) | 140 | 70 |
| Workday (1) | 1,839 | 411 |
| Zscaler (1) | 114 | 22 |
| | | 82,956 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Technology Hardware, Storage & Peripherals 6.9% | | |
| Apple | 234,294 | 49,347 |
| Pure Storage, Class A (1) | 8,944 | 575 |
| Western Digital (1) | 10,574 | 801 |
| | | 50,723 |
| Total Information Technology | | 236,568 |
| MATERIALS 2.0% |
| Chemicals 1.0% | | |
| CF Industries Holdings | 8,586 | 636 |
| Linde | 11,353 | 4,982 |
| Mosaic | 16,468 | 476 |
| RPM International | 1,502 | 162 |
| Sherwin-Williams | 4,267 | 1,273 |
| | | 7,529 |
| Construction Materials 0.2% | | |
| Vulcan Materials | 4,221 | 1,050 |
| | | 1,050 |
| Containers & Packaging 0.2% | | |
| Avery Dennison | 704 | 154 |
| Ball | 12,768 | 766 |
| Packaging of America | 3,708 | 677 |
| WestRock | 2,702 | 136 |
| | | 1,733 |
| Metals & Mining 0.5% | | |
| Agnico Eagle Mines | 7,460 | 488 |
| Franco-Nevada | 3,680 | 436 |
| Freeport-McMoRan | 29,626 | 1,440 |
| Steel Dynamics | 7,926 | 1,026 |
| | | 3,390 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Paper & Forest Products 0.1% | | |
| West Fraser Timber | 8,521 | 655 |
| | | 655 |
| Total Materials | | 14,357 |
| REAL ESTATE 1.9% |
| Health Care REITs 0.2% | | |
| Welltower, REIT | 12,708 | 1,325 |
| | | 1,325 |
| Industrial REITs 0.4% | | |
| Prologis, REIT | 16,936 | 1,902 |
| Rexford Industrial Realty, REIT | 21,734 | 969 |
| | | 2,871 |
| Real Estate Management & Development 0.1% | | |
| CBRE Group, Class A (1) | 4,206 | 375 |
| CoStar Group (1) | 4,322 | 320 |
| | | 695 |
| Residential REITs 0.4% | | |
| American Homes 4 Rent, Class A, REIT | 8,515 | 316 |
| AvalonBay Communities, REIT | 3,920 | 811 |
| Camden Property Trust, REIT | 200 | 22 |
| Essex Property Trust, REIT | 4,158 | 1,132 |
| Sun Communities, REIT | 4,215 | 507 |
| | | 2,788 |
| Retail REITs 0.1% | | |
| Kimco Realty, REIT | 16,233 | 316 |
| Regency Centers, REIT | 4,267 | 266 |
| Simon Property Group, REIT | 3,683 | 559 |
| | | 1,141 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| Specialized REITs 0.7% | | |
| American Tower, REIT | 8,746 | 1,700 |
| CubeSmart, REIT | 4,467 | 202 |
| Equinix, REIT | 2,620 | 1,982 |
| Extra Space Storage, REIT | 335 | 52 |
| Public Storage, REIT | 3,933 | 1,132 |
| Weyerhaeuser, REIT | 4,377 | 124 |
| | | 5,192 |
| Total Real Estate | | 14,012 |
| UTILITIES 2.2% |
| Electric Utilities 1.5% | | |
| Constellation Energy | 7,734 | 1,549 |
| Exelon | 6,000 | 208 |
| FirstEnergy | 21,461 | 822 |
| NextEra Energy | 50,080 | 3,546 |
| PG&E | 127,107 | 2,219 |
| PPL | 5,138 | 142 |
| Southern | 20,623 | 1,600 |
| Xcel Energy | 17,174 | 917 |
| | | 11,003 |
| Gas Utilities 0.1% | | |
| Atmos Energy | 4,400 | 513 |
| | | 513 |
| Independent Power & Renewable Electricity Producer 0.0% | | |
| Vistra | 3,384 | 291 |
| | | 291 |
| Multi-Utilities 0.6% | | |
| Ameren | 17,076 | 1,214 |
| CenterPoint Energy | 33,375 | 1,034 |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
| | Shares | $ Value |
| (Cost and value in $000s) | | |
| CMS Energy | 3,857 | 230 |
| Dominion Energy | 26,490 | 1,298 |
| NiSource | 25,279 | 728 |
| | | 4,504 |
| Total Utilities | | 16,311 |
| Total Common Stocks (Cost $677,535) | | 727,770 |
| SHORT-TERM INVESTMENTS 0.3% |
| Money Market Funds 0.3% | | |
| State Street Institutional U.S. Government Money Market Fund, 5.25% (3) | 2,364,427 | 2,364 |
| Total Short-Term Investments (Cost $2,364) | | 2,364 |
| SECURITIES LENDING COLLATERAL 0.1% |
| Investments in a Pooled Account through Securities Lending Program with State Street Bank 0.1% | | |
| Money Market Funds 0.1% | | |
| T. Rowe Price Government Reserve Fund, 5.38% (3)(4) | 468,792 | 469 |
| Total Investments in a Pooled Account through Securities Lending Program with State Street Bank | | 469 |
| Total Securities Lending Collateral (Cost $469) | | 469 |
Total Investments in Securities
100.1% of Net Assets (Cost $680,368) | | $730,603 |
| | |
| ‡ | Shares are denominated in U.S. dollars unless otherwise noted. |
| (1) | Non-income producing. |
| (2) | All or a portion of this security is on loan at June 30, 2024. See Note 3. |
| (3) | Seven-day yield |
| (4) | Affiliated Companies |
| ADR | American Depositary Receipts |
| REIT | A domestic Real Estate Investment Trust whose distributions pass-through with original tax character to the shareholder |
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
AFFILIATED COMPANIES
($000s)
The fund may invest in certain securities that are considered affiliated companies. As defined by the 1940 Act, an affiliated company is one in which the fund owns 5% or more of the outstanding voting securities, or a company that is under common ownership or control. The following securities were considered affiliated companies for all or some portion of the six months ended June 30, 2024. Net realized gain (loss), investment income, change in net unrealized gain/loss, and purchase and sales cost reflect all activity for the period then ended.
| Affiliate | Net Realized Gain
(Loss) | Changes in Net
Unrealized
Gain/Loss | Investment
Income |
| T. Rowe Price Government Reserve Fund | $— | $— | $—++ |
| Totals | $—# | $— | $—+ |
| Supplementary Investment Schedule |
| Affiliate | Value
12/31/23 | Purchase
Cost | Sales
Cost | Value
6/30/24 |
| T. Rowe Price Government Reserve Fund | $195 | ¤ | ¤ | $469 |
| | Total | | | $469^ |
| ++ | Excludes earnings on securities lending collateral, which are subject to rebates and fees as described in Note 3. |
| # | Capital gain distributions from mutual funds represented $0 of the net realized gain (loss). |
| + | Investment income comprised $0 of dividend income and $0 of interest income. |
| ¤ | Purchase and sale information not shown for cash management funds. |
| ^ | The cost basis of investments in affiliated companies was $469. |
The accompanying notes are an integral part of these financial statements.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
June 30, 2024 Unaudited
STATEMENT OF ASSETS AND LIABILITIES
($000s, except shares and per share amounts)
| Assets | |
| Investments in securities, at value (cost $680,368) | $730,603 |
| Receivable for shares sold | 20,437 |
| Receivable for investment securities sold | 2,658 |
| Dividends receivable | 344 |
| Total assets | 754,042 |
| Liabilities | |
| Payable for investment securities purchased | 23,335 |
| Obligation to return securities lending collateral | 469 |
| Investment management and administrative fees payable | 179 |
| Due to custodian | 8 |
| Total liabilities | 23,991 |
| NET ASSETS | $730,051 |
| Net assets consists of: | |
| Total distributable earnings (loss) | $48,792 |
Paid-in capital applicable to 21,255,000 shares of $0.0001 par value
capital stock outstanding; 4,000,000,000 shares authorized | 681,259 |
| NET ASSETS | $730,051 |
| NET ASSET VALUE PER SHARE | $34.35 |
The accompanying notes are an integral part of these financial statements.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Unaudited
STATEMENT OF OPERATIONS
($000s)
| | 6 Months
Ended |
| | 6/30/24 |
| Investment Income (Loss) | |
| Income | |
| Dividend (net of foreign taxes of $3) | $1,649 |
| Securities lending | 2 |
| Total income | 1,651 |
| Investment management and administrative expense | 425 |
| Net investment income | 1,226 |
| Realized and Unrealized Gain / Loss | |
| Net realized gain (loss) | |
| Securities | (1,208) |
| In-kind redemptions | 349 |
| Net realized loss | (859) |
| Change in net unrealized gain / loss on securities | 41,324 |
| Net realized and unrealized gain / loss | 40,465 |
| INCREASE IN NET ASSETS FROM OPERATIONS | $41,691 |
The accompanying notes are an integral part of these financial statements.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Unaudited
STATEMENT OF CHANGES IN NET ASSETS
($000s)
| | 6 Months
Ended | | Year
Ended |
| | 6/30/24 | | 12/31/23 |
| Increase (Decrease) in Net Assets | | | |
| Operations | | | |
| Net investment income | $1,226 | | $400 |
| Net realized loss | (859) | | (253) |
| Change in net unrealized gain / loss | 41,324 | | 10,145 |
| Increase in net assets from operations | 41,691 | | 10,292 |
| Distributions to shareholders | | | |
| Net earnings | — | | (379) |
| Capital share transactions* | | | |
| Shares sold | 594,206 | | 63,393 |
| Shares redeemed | (962) | | (1,254) |
| Increase in net assets from capital share transactions | 593,244 | | 62,139 |
| Net Assets | | | |
| Increase during period | 634,935 | | 72,052 |
| Beginning of period | 95,116 | | 23,064 |
| End of period | $730,051 | | $95,116 |
| *Share information | | | |
| Shares sold | 18,045 | | 2,275 |
| Shares redeemed | (30) | | (50) |
| Increase in shares outstanding | 18,015 | | 2,225 |
The accompanying notes are an integral part of these financial statements.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Unaudited
NOTES TO FINANCIAL STATEMENTS
T. Rowe Price Exchange-Traded Funds, Inc. (the corporation) is registered under the Investment Company Act of 1940 (the 1940 Act). The U.S. Equity Research ETF (the fund) is an open-end management investment company established by the corporation. During the reporting period, the fund’s classification changed from nondiversified to diversified. The fund seeks to provide long-term capital growth.
The fund is considered an actively-managed exchange-traded fund (ETF) that does not disclose its portfolio holdings daily, which is different from a traditional ETF and may create additional risks. In order to provide market participants with information on the fund’s investments, the fund publishes a “Proxy Portfolio” on its website daily. A Proxy Portfolio is a basket of securities that is designed to closely track the daily performance of the fund’s portfolio holdings. While the Proxy Portfolio includes some of the fund’s holdings, it is not the fund’s actual portfolio. The fund does disclose its full portfolio holdings on a quarterly basis, similar to mutual funds.
NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES
Basis of Preparation
The fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 (ASC 946). The accompanying financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), including, but not limited to, ASC 946. GAAP requires the use of estimates made by management. Management believes that estimates and valuations are appropriate; however, actual results may differ from those estimates, and the valuations reflected in the accompanying financial statements may differ from the value ultimately realized upon sale or maturity.
Investment Transactions, Investment Income, and Distributions
Investment transactions are accounted for on the trade date basis. Income and expenses are recorded on the accrual basis. Realized gains and losses are reported on the identified cost basis. Income tax-related interest and penalties, if incurred, are recorded as income tax expense. Dividends received from other investment companies are reflected as dividend income; capital gain distributions are reflected as realized gain/loss. Dividend income and capital gain distributions
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
are recorded on the ex-dividend date. Distributions from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available. Non-cash dividends, if any, are recorded at the fair market value of the asset received. Proceeds from litigation payments, if any, are included in either net realized gain (loss) or change in net unrealized gain/loss from securities. Distributions to shareholders are recorded on the ex-dividend date. Income distributions, if any, are declared and paid annually. A capital gain distribution, if any, may also be declared and paid by the fund annually. Dividends and distributions cannot be automatically reinvested in additional shares of the fund.
Capital Transactions
The fund issues and redeems shares at its net asset value (NAV) only with Authorized Participants and only in large blocks of 5,000 shares (each, a “Creation Unit”). The fund’s NAV per share is computed at the close of the New York Stock Exchange (NYSE). However, the NAV per share may be calculated at a time other than the normal close of the NYSE if trading on the NYSE is restricted, if the NYSE closes earlier, or as may be permitted by the SEC. Individual fund shares may not be purchased or redeemed directly with the fund. An Authorized Participant may purchase or redeem a Creation Unit of the fund each business day that the fund is open in exchange for the delivery of a designated portfolio of in-kind securities and/or cash. When purchasing or redeeming Creation Units, Authorized Participants are also required to pay a fixed and/or variable purchase or redemption transaction fee as well as any applicable additional variable charge to defray the transaction cost to a fund.
Individual fund shares may be purchased and sold only on a national securities exchange through brokers. Shares are listed for trading on NYSE Arca, Inc. (NYSE Arca) and because the shares will trade at market prices rather than NAV, shares may trade at prices greater than NAV (at a premium), at NAV, or less than NAV (at a discount). The fund’s shares are ordinarily valued as of the close of regular trading (normally 4:00 p.m. Eastern time) on each day that the NYSE Arca is open.
Indemnification
In the normal course of business, the fund may provide indemnification in connection with its officers and directors, service providers, and/or private company investments. The fund’s maximum exposure under these arrangements is unknown; however, the risk of material loss is currently considered to be remote.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
NOTE 2 – VALUATION
Fair Value
The fund’s financial instruments are valued at the close of the NYSE and are reported at fair value, which GAAP defines as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fund’s Board of Directors (the Board) has designated T. Rowe Price Associates, Inc. as the fund’s valuation designee (Valuation Designee). Subject to oversight by the Board, the Valuation Designee performs the following functions in performing fair value determinations: assesses and manages valuation risks; establishes and applies fair value methodologies; tests fair value methodologies; and evaluates pricing vendors and pricing agents. The duties and responsibilities of the Valuation Designee are performed by its Valuation Committee. The Valuation Designee provides periodic reporting to the Board on valuation matters.
Various valuation techniques and inputs are used to determine the fair value of financial instruments. GAAP establishes the following fair value hierarchy that categorizes the inputs used to measure fair value:
Level 1 – quoted prices (unadjusted) in active markets for identical financial instruments that the fund can access at the reporting date
Level 2 – inputs other than Level 1 quoted prices that are observable, either directly or indirectly (including, but not limited to, quoted prices for similar financial instruments in active markets, quoted prices for identical or similar financial instruments in inactive markets, interest rates and yield curves, implied volatilities, and credit spreads)
Level 3 – unobservable inputs (including the Valuation Designee’s assumptions in determining fair value)
Observable inputs are developed using market data, such as publicly available information about actual events or transactions, and reflect the assumptions that market participants would use to price the financial instrument. Unobservable inputs are those for which market data are not available and are developed using the best information available about the assumptions that market participants would use to price the financial instrument. GAAP requires valuation techniques to maximize the use of relevant observable inputs and minimize the use of unobservable inputs. When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the fair value hierarchy based on the lowest-level input that is significant to the fair value of the financial
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
instrument. Input levels are not necessarily an indication of the risk or liquidity associated with financial instruments at that level but rather the degree of judgment used in determining those values.
Valuation Techniques
Equity securities, including exchange-traded funds, listed or regularly traded on a securities exchange or in the over-the-counter (OTC) market are valued at the last quoted sale price or, for certain markets, the official closing price at the time the valuations are made. A security that is listed or traded on more than one exchange is valued at the quotation on the exchange determined to be the primary market for such security. Listed securities not traded on a particular day are valued at the mean of the closing bid and asked prices for domestic securities.
Investments in mutual funds are valued at the mutual fund’s closing NAV per share on the day of valuation. Assets and liabilities other than financial instruments, including short-term receivables and payables, are carried at cost, or estimated realizable value, if less, which approximates fair value.
Investments for which market quotations are not readily available or deemed unreliable are valued at fair value as determined in good faith by the Valuation Designee. The Valuation Designee has adopted methodologies for determining the fair value of investments for which market quotations are not readily available or deemed unreliable, including the use of other pricing sources. Factors used in determining fair value vary by type of investment and may include market or investment specific considerations. The Valuation Designee typically will afford greatest weight to actual prices in arm’s length transactions, to the extent they represent orderly transactions between market participants, transaction information can be reliably obtained, and prices are deemed representative of fair value. However, the Valuation Designee may also consider other valuation methods such as market-based valuation multiples; a discount or premium from market value of a similar, freely traded security of the same issuer; discounted cash flows; yield to maturity; or some combination. Fair value determinations are reviewed on a regular basis. Because any fair value determination involves a significant amount of judgment, there is a degree of subjectivity inherent in such pricing decisions. Fair value prices determined by the Valuation Designee could differ from those of other market participants, and it is possible that the fair value determined for a security may be materially different from the value that could be realized upon the sale of that security.
Valuation Inputs
On June 30, 2024, all of the fund’s financial instruments were classified as Level 1, based on the inputs used to determine their fair values.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
NOTE 3 – OTHER INVESTMENT TRANSACTIONS
Consistent with its investment objective, the fund engages in the following practices to manage exposure to certain risks and/or to enhance performance. The investment objective, policies, program, and risk factors of the fund are described more fully in the fund’s prospectus and Statement of Additional Information.
Securities Lending
The fund may lend its securities to approved borrowers to earn additional income. Its securities lending activities are administered by a lending agent in accordance with a securities lending agreement. Security loans generally do not have stated maturity dates, and the fund may recall a security at any time. The fund receives collateral in the form of cash or U.S. government securities. Collateral is maintained over the life of the loan in an amount not less than the value of loaned securities; any additional collateral required due to changes in security values is delivered to the fund the next business day. Cash collateral is invested in accordance with investment guidelines approved by fund management. Additionally, the lending agent indemnifies the fund against losses resulting from borrower default. Although risk is mitigated by the collateral and indemnification, the fund could experience a delay in recovering its securities and a possible loss of income or value if the borrower fails to return the securities, collateral investments decline in value, and the lending agent fails to perform. Securities lending revenue consists of earnings on invested collateral and borrowing fees, net of any rebates to the borrower, compensation to the lending agent, and other administrative costs. In accordance with GAAP, investments made with cash collateral are reflected in the accompanying financial statements, but collateral received in the form of securities is not. At June 30, 2024, the value of loaned securities was $439,000; the value of cash collateral and related investments was $469,000.
Other
Purchases and sales of portfolio securities excluding in-kind transactions and short-term securities aggregated $67,604,000 and $66,270,000, respectively, for the six months ended June 30, 2024. Portfolio securities received and delivered through in-kind transactions aggregated $592,273,000 and $959,000, respectively, for the six months ended June 30, 2024.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
NOTE 4 – FEDERAL INCOME TAXES
Generally, no provision for federal income taxes is required since the fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code and distribute to shareholders all of its taxable income and gains. Distributions determined in accordance with federal income tax regulations may differ in amount or character from net investment income and realized gains for financial reporting purposes. Financial reporting records are adjusted for permanent book/tax differences to reflect tax character but are not adjusted for temporary differences. The amount and character of tax-basis distributions and composition of net assets are finalized at fiscal year-end; accordingly, tax-basis balances have not been determined as of the date of this report.
The fund intends to retain realized gains to the extent of available capital loss carryforwards. Net realized capital losses may be carried forward indefinitely to offset future realized capital gains. As of December 31, 2023, the fund had $1,720,000 of available capital loss carryforwards.
At June 30, 2024, the cost of investments (including derivatives, if any) for federal income tax purposes was $680,501,000. Net unrealized gain aggregated $50,102,000 at period-end, of which $53,479,000 related to appreciated investments and $3,377,000 related to depreciated investments.
NOTE 5 – FOREIGN TAXES
The fund is subject to foreign income taxes imposed by certain countries in which it invests. Additionally, capital gains realized upon disposition of securities issued in or by certain foreign countries are subject to capital gains tax imposed by those countries. All taxes are computed in accordance with the applicable foreign tax law, and, to the extent permitted, capital losses are used to offset capital gains. Taxes attributable to income are accrued by the fund as a reduction of income. Current and deferred tax expense attributable to capital gains is reflected as a component of realized or change in unrealized gain/loss on securities in the accompanying financial statements. To the extent that the fund has country specific capital loss carryforwards, such carryforwards are applied against net unrealized gains when determining the deferred tax liability. Any deferred tax liability incurred by the fund is included in either Other liabilities or Deferred tax liability on the accompanying Statement of Assets and Liabilities.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
NOTE 6 – RELATED PARTY TRANSACTIONS
The fund is managed by T. Rowe Price Associates, Inc. (Price Associates), a wholly owned subsidiary of T. Rowe Price Group, Inc. (Price Group). The investment management and administrative agreement between the fund and Price Associates provides for an all-inclusive annual fee equal to 0.34% of the fund’s average daily net assets. The fee is computed daily and paid monthly. The all-inclusive fee covers investment management services and ordinary, recurring operating expenses but does not cover interest and borrowing expenses; taxes; brokerage commissions and other transaction costs; fund proxy expenses; and nonrecurring and extraordinary expenses.
T. Rowe Price Investment Services, Inc. (Investment Services) serves as distributor to the fund. Pursuant to an underwriting agreement, no compensation for any distribution services provided is paid to Investment Services by the fund.
Cash collateral from securities lending, if any, is invested in the T. Rowe Price Government Reserve Fund (the Price Reserve Fund), a money market fund offered as a short-term investment option to mutual funds, trusts, and other accounts managed by Price Associates or its affiliates and is not available for direct purchase by members of the public. The Price Reserve Fund does not pay investment management fees.
As of June 30, 2024, T. Rowe Price Group, Inc., or its wholly owned subsidiaries, owned 1,045,014 shares of the fund, representing 5% of the fund’s net assets.
The fund may participate in securities purchase and sale transactions with other funds or accounts advised by Price Associates (cross trades), in accordance with procedures adopted by the fund’s Board and Securities and Exchange Commission rules, which require, among other things, that such purchase and sale cross trades be effected at the independent current market price of the security. During the six months ended June 30, 2024, the fund had no purchases or sales cross trades with other funds or accounts advised by Price Associates.
NOTE 7 – BORROWING
At June 30, 2024, the fund had outstanding borrowings from State Street Bank of $8,000 at an annual rate of 0.00%.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
NOTE 8 – OTHER MATTERS
Unpredictable environmental, political, social and economic events, including but not limited to, environmental or natural disasters, war and conflict (including Russia’s military invasion of Ukraine and the conflict in Israel, Gaza and surrounding areas), terrorism, geopolitical developments (including trading and tariff arrangements, sanctions and cybersecurity attacks), and public health epidemics (including the global outbreak of COVID-19) and similar public health threats, may significantly affect the economy and the markets and issuers in which a fund invests. The extent and duration of such events and resulting market disruptions cannot be predicted. These and other similar events may cause instability across global markets, including reduced liquidity and disruptions in trading markets, while some events may affect certain geographic regions, countries, sectors, and industries more significantly than others, and exacerbate other pre-existing political, social, and economic risks. The fund’s performance could be negatively impacted if the value of a portfolio holding were harmed by these or such events. Management actively monitors the risks and financial impacts arising from such events.
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Approval of Investment Management Agreement
Each year, the fund’s Board of Directors (Board) considers the continuation of the investment management agreement (Advisory Contract) between the fund and its investment adviser, T. Rowe Price Associates, Inc. (Adviser). In that regard, at a meeting held on March 11–12, 2024 (Meeting), the Board, including all of the fund’s independent directors present in person at the Meeting, approved the continuation of the fund’s Advisory Contract. At the Meeting, the Board considered the factors and reached the conclusions described below relating to the selection of the Adviser and the approval of the Advisory Contract. The independent directors were assisted in their evaluation of the Advisory Contract by independent legal counsel from whom they received separate legal advice and with whom they met separately.
In providing information to the Board, the Adviser was guided by a detailed set of requests for information submitted by independent legal counsel on behalf of the independent directors. In considering and approving the continuation of the Advisory Contract, the Board considered the information it believed was relevant, including, but not limited to, the information discussed below. The Board considered not only the specific information presented in connection with the Meeting, but also the knowledge gained over time through interaction with the Adviser about various topics. The Board meets regularly and, at each of its meetings, covers an extensive agenda of topics and materials and considers factors that are relevant to its annual consideration of the renewal of the T. Rowe Price funds’ advisory contracts, including performance and the services and support provided to the funds and their shareholders.
Services Provided by the Adviser
The Board considered the nature, quality, and extent of the services provided to the fund by the Adviser. These services included, but were not limited to, directing the fund’s investments in accordance with its investment program and the overall management of the fund’s portfolio, as well as a variety of related activities such as financial, investment operations, and administrative services; compliance; maintaining the fund’s records and registrations; and shareholder communications. The Board also reviewed the background and experience of the Adviser’s senior management team and investment personnel involved in the management of the fund, as well as the Adviser’s compliance record. The Board concluded that the information it considered with respect to the nature, quality, and extent of the services provided by the Adviser, as well as the other factors considered at the Meeting, supported the Board’s approval of the continuation of the Advisory Contract.
Investment Performance of the Fund
The Board took into account discussions with the Adviser and detailed reports that it regularly receives throughout the year on relative and absolute performance for the T. Rowe Price funds. In connection with the Meeting, the Board reviewed information provided by the Adviser that compared the fund’s total returns, as well as a wide variety of other previously agreed-upon performance measures and market data,
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Approval of Investment Management Agreement (continued)
against relevant benchmark indexes and peer groups of funds with similar investment programs for various periods through December 31, 2023. Additionally, the Board reviewed the fund’s relative performance information as of September 30, 2023, which ranked the returns of the fund for various periods against a universe of funds with similar investment programs selected by Broadridge, an independent provider of mutual fund data.
In the course of its deliberations, the Board considered performance information provided throughout the year and in connection with the Advisory Contract review at the Meeting, as well as information provided during investment review meetings conducted with portfolio managers and senior investment personnel during the course of the year regarding the fund’s performance. The Board also considered relevant factors, such as overall market conditions and trends that could adversely impact the fund’s performance, the length of the fund’s performance track record, and how closely the fund’s strategies align with its benchmarks and peer groups. The Board concluded that the information it considered with respect to the fund’s performance, as well as the other factors considered at the Meeting, supported the Board’s approval of the continuation of the Advisory Contract.
Costs, Benefits, Profits, and Economies of Scale
The Board reviewed detailed information regarding the revenues received by the Adviser under the Advisory Contract and other direct and indirect benefits that the Adviser (and its affiliates) may have realized from its relationship with the fund. In considering soft-dollar arrangements pursuant to which research may be received from broker-dealers that execute the fund’s portfolio transactions, the Board noted that during 2023 the Adviser paid the costs of research services for all client accounts that it advises, including the T. Rowe Price funds. However, effective January 1, 2024, the Adviser will begin using brokerage commissions in connection with certain T. Rowe Price funds’ securities transactions to pay for research when permissible.
The Board received information on the estimated costs incurred and profits realized by the Adviser from managing the T. Rowe Price funds. While the Board did not review information regarding profits realized from managing the fund in particular because the fund had either not achieved sufficient portfolio asset size or not recognized sufficient revenues to produce meaningful profit margin percentages, the Board concluded that the Adviser’s profits were reasonable in light of the services provided to the T. Rowe Price mutual funds and ETFs.
The Board also considered whether the fund benefits under the fee levels set forth in the Advisory Contract or otherwise from any economies of scale realized by the Adviser. Under the Advisory Contract, the fund pays the Adviser an all-inclusive management fee, which is based on the fund’s average daily net assets. The all-inclusive management fee includes investment management services and provides for the Adviser to pay all of the fund’s ordinary, recurring operating expenses
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Approval of Investment Management Agreement (continued)
except for interest and borrowing expenses, taxes, brokerage commissions and other transaction costs, fund proxy expenses, and any nonrecurring extraordinary expenses. The Adviser has generally implemented an all-inclusive management fee structure in situations where a fixed total expense ratio is useful for purposes of providing certainty of fees and expenses for investors and such a fee structure is typically used by other ETFs offered by competitors. The Adviser has historically sought to set the initial all-inclusive management fee rate at levels below the expense ratios of comparable funds to take into account potential future economies of scale. In addition, the assets of the fund are included in the calculation of the group fee rate, which serves as a component of the management fee for many T. Rowe Price funds and declines at certain asset levels based on the combined average net assets of most of the T. Rowe Price mutual funds and ETFs (including the fund). Although the fund does not have a group fee component to its management fee, its assets are included in the calculation because certain resources utilized to operate the fund are shared with other T. Rowe Price funds.
In addition, the Board noted that the fund potentially shares in indirect economies of scale through the Adviser’s ongoing investments in its business in support of the T. Rowe Price funds, including investments in trading systems, technology, and regulatory support enhancements, and the ability to possibly negotiate lower fee arrangements with third-party service providers. The Board concluded that the advisory fee structure for the fund provides for a reasonable sharing of benefits from any economies of scale with the fund’s investors.
Fees and Expenses
The Board was provided with information regarding industry trends in management fees and expenses. Among other things, the Board reviewed data for peer groups that were compiled by Broadridge, which compared: (i) actual management fees, nonmanagement expenses, and total expenses of the fund with a group of competitor funds selected by Broadridge (Expense Group) and (ii) actual management fees, nonmanagement expenses, and total expenses of the fund with a broader set of funds within the Lipper investment classification (Expense Universe). The Board considered the fund’s actual management fee rate (which reflects the management fees actually received from the fund by the Adviser after any applicable waivers, reductions, or reimbursements), operating expenses, and total expenses (which reflect the net total expense ratio of the fund after any waivers, reductions, or reimbursements) in comparison with the information for the Broadridge peer groups. Broadridge generally constructed the peer groups by seeking the most comparable funds based on similar investment classifications and objectives, expense structure, asset size, and operating components and attributes and ranked funds into quintiles, with the first quintile representing the funds with the lowest relative expenses and the fifth quintile representing the funds with the highest relative expenses. The information provided to the Board indicated that the fund’s actual management fee
T. ROWE PRICE U.S. EQUITY RESEARCH ETF
Approval of Investment Management Agreement (continued)
rate ranked in the first quintile (Expense Group) and second quintile (Expense Universe) and the fund’s total expenses ranked in the first quintile (Expense Group) and second quintile (Expense Universe).
The Board also reviewed the fee schedules for other investment portfolios with similar mandates that are advised or subadvised by the Adviser and its affiliates, including separately managed accounts for institutional and individual investors; subadvised funds; and other sponsored investment portfolios, including collective investment trusts and pooled vehicles organized and offered to investors outside the United States. Management provided the Board with information about the Adviser’s responsibilities and services provided to subadvisory and other institutional account clients, including information about how the requirements and economics of the institutional business are fundamentally different from those of the proprietary mutual fund business. The Board considered information showing that the Adviser’s mutual fund business is generally more complex from a business and compliance perspective than its institutional account business and considered various relevant factors, such as the broader scope of operations and oversight, more extensive shareholder communication infrastructure, greater asset flows, heightened business risks, and differences in applicable laws and regulations associated with the Adviser’s proprietary mutual fund business. In assessing the reasonableness of the fund’s management fee rate, the Board considered the differences in the nature of the services required for the Adviser to manage its mutual fund business versus managing a discrete pool of assets as a subadviser to another institution’s mutual fund or for an institutional account and that the Adviser generally performs significant additional services and assumes greater risk in managing the fund and other T. Rowe Price funds than it does for institutional account clients, including subadvised funds.
On the basis of the information provided and the factors considered, the Board concluded that the fees paid by the fund under the Advisory Contract are reasonable.
Approval of the Advisory Contract
As noted, the Board approved the continuation of the Advisory Contract. No single factor was considered in isolation or to be determinative to the decision. Rather, the Board concluded, in light of a weighting and balancing of all factors considered, that it was in the best interests of the fund and its shareholders for the Board to approve the continuation of the Advisory Contract (including the fees to be charged for services thereunder).
This page intentionally left blank.
This page intentionally left blank.
This page intentionally left blank.
100 East Pratt Street
Baltimore, MD 21202
Call 1-800-638-5660 to request a prospectus or summary prospectus; each includes investment objectives, risks, fees, expenses, and other information that you should read and consider carefully before investing.
T. Rowe Price Investment Services, Inc.
Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.
Not applicable.
Item 9. Proxy Disclosures for Open-End Management Investment Companies.
Not applicable.
Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.
Remuneration paid to Directors is included in Item 7 of this Form N-CSR and/or the Statement of Additional Information.
Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.
If applicable, see Item 7.
Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable.
Item 13. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable.
Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable.
Item 15. Submission of Matters to a Vote of Security Holders.
There has been no change to the procedures by which shareholders may recommend nominees to the registrant’s board of directors.
Item 16. Controls and Procedures.
(a) The registrant’s principal executive officer and principal financial officer have evaluated the registrant’s disclosure controls and procedures within 90 days of this filing and have concluded that the registrant’s disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.
(b) The registrant’s principal executive officer and principal financial officer are aware of no change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.
Not applicable.
Item 18. Recovery of Erroneously Awarded Compensation.
Not applicable.
Item 19. Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
| T. Rowe Price U.S. Equity Research ETF |
| | |
| By | | /s/ David Oestreicher | | |
| | David Oestreicher | | |
| | Principal Executive Officer | | |
| | |
| Date | | August 20, 2024 | | |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | |
| By | | /s/ David Oestreicher | | |
| | David Oestreicher | | |
| | Principal Executive Officer | | |
| | |
| Date | | August 20, 2024 | | |
| | | | |
| By | | /s/ Alan S. Dupski | | |
| | Alan S. Dupski | | |
| | Principal Financial Officer | | |
| | |
| Date | | August 20, 2024 | | |
